Aratana Therapeutics (PETX): Cutting PT - Jefferies

November 16, 2016 7:32 AM EST
Get Alerts PETX Hot Sheet
Price: $7.12 +1.42%

Rating Summary:
    10 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade PETX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, David Gu, reiterated his Buy rating on shares of Aratana Therapeutics (NASDAQ: PETX) but cut his price target to $11 noting that Entyce and Nocita remain on track and are the key drivers of valuation.

AT-018 development in recurrent atopic dermatitis was discontinued, and he sees modest impact on the shares as due to the asymmetrical upside for this underthe-radar asset. That said, he cut the price target to $11 from $13 to reflect development updates.

For an analyst ratings summary and ratings history on Aratana Therapeutics click here. For more ratings news on Aratana Therapeutics click here.

Shares of Aratana Therapeutics closed at $7.94 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment